Linear Park Marketing, Inc. entered into letter of intent to acquire Dynamo Capital Corp. (TSXV:DDD.P) in a reverse merger transaction for CAD 6.5 million on April 3, 2020. As per the letter of intent, Dynamo will issue to the shareholders of Linear on a pro rata basis 100 million common shares of the Dynamo Capital Corp. On completion of the transaction, the former shareholders of Linear will own a majority of the issued and outstanding shares of the Dynamo. In connection with the Transaction, it is anticipated that Dynamo will complete a non-brokered private placement of common shares of Dynamo, at the price of CAD 0.4 per share, for minimum proceeds of CAD 1 million. Upon completion of the transaction the resulting Issuer is expected to change its name to Linear Holdings Inc. or such other name as determined by Linear and the resulting Issuer is expected to be listed as a Tier 2 industrial issuer under the exchange's rules. As at June 15, 2020, Dynamo Capital Corp and Linear are negotiating an extension on the letter of intent. At the closing of the transaction, the board of directors will be comprised of the following four directors; Mark Livingston will serve as the resulting issuer's Chief Executive Officer, Dan Koziol will serve as the resulting issuer's Chief Marketing Officer, George Callas - Director of resulting issuer and Kelly Lenahan will serve as the resulting issuer's Chief Financial Officer. The Transaction is not a non-arm's length transaction, as such term is defined in Policy 2.4 - Capital Pool Companies of the Corporate Finance Manual of the TSX Venture Exchange and it is therefore anticipated that approval of the shareholders of the Dynamo Capital in respect of the transaction will not be required. Completion of the transaction is subject to a number of conditions, including but not limited to, exchange acceptance and if applicable pursuant to exchange requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. In addition completion of the transaction is also subject to the following conditions, among others: (i) completion of the UPPR Acquisition and the PrimaPharma Acquisition; (ii) negotiation and execution of the definitive agreement prior to April 30, 2020; (iii) receipt of all requisite regulatory, stock exchange, court or governmental approvals, authorizations and consents; (iv) completion of due diligence to the satisfaction of both parties; (v) completion of the Private Placement and (vi) if applicable, each party having received all necessary approvals from their shareholders.